Collegium Pharmaceutical, Inc. COLL Deferred royalty obligation
Deferred royalty obligation at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept coll:DeferredRoyaltyLiabilityNonCurrent.
The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Collegium Pharmaceutical, Inc.'s deferred royalty obligation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Collegium Pharmaceutical, Inc.'s deferred royalty obligation?
- Collegium Pharmaceutical, Inc. (COLL) reported deferred royalty obligation of $121.63M in Q1 2026.
- How has Collegium Pharmaceutical, Inc.'s deferred royalty obligation changed year-over-year?
- Collegium Pharmaceutical, Inc.'s deferred royalty obligation increased by 0.1% year-over-year, from $121.52M to $121.63M.
- What does deferred royalty obligation mean?
- This represents the long-term portion of obligations to pay royalties to third parties, typically arising from licensing agreements or the acquisition of intellectual property rights. It reflects future cash commitments tied to the commercial success or sales of specific products. Tracking this liability is important for understanding long-term margin pressure and the cost structure associated with licensed technologies.